Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
Crossref DOI link: https://doi.org/10.1186/s12962-017-0077-4
Published Online: 2017-07-21
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
McEwan, Phil
Webster, Samantha
Ward, Thomas
Brenner, Michael
Kalsekar, Anupama
Yuan, Yong
Funding for this research was provided by:
Bristol-Myers Squibb